Skip to main content

Table 3 Comparing the within- and between-group blood counts measured at baseline and on days 7 and 15 in each course of chemotherapy

From: Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

Courses

 

PDL Group (Median)

p-value*

PGL Group (Median)

p-value*

p-value**

D0

D7

D15

D0

D7

D15

1

WBC

8900

4100

5850

< 0.001

9550

3850

5750

< 0.001

0.295

Hb

13.20

13.00

13.00

< 0.001

12.80

12.35

12.25

< 0.001

0.159

Plt

280,000

124,000

173,000

< 0.001

248,500

124,000

168,000

< 0.001

0.416

Neut

75

50

85

< 0.001

70

50

85

< 0.001

0.312

Lymph

25

50

15

< 0.001

27

50

15

< 0.001

0.130

ANC

6545

2050

5025

< 0.001

6830

1660

4600

< 0.001

0.327

2

WBC

5850

3100

4400

< 0.001

5750

3000

4500

< 0.001

0.866

Hb

13.00

13.00

12.90

< 0.001

12.25

12.20

12.20

< 0.001

0.307

Plt

173,000

111,000

156,000

< 0.001

168,000

107,000

156,000

< 0.001

0.468

Neut

85

50

85

< 0.001

85

50

86

< 0.001

0.504

Lymph

15

50

13

< 0.001

15

50

14

< 0.001

0.243

ANC

5025

1575

3838

< 0.001

4600

1400

3895

< 0.001

0.950

3

WBC

4400

2450

3950

< 0.001

4500

2500

3950

< 0.001

0.820

Hb

12.90

12.90

12.30

< 0.001

12.20

12.00

12.00

< 0.001

0.107

Plt

156,000

101,000

139,000

< 0.001

156,000

100,000

146,000

< 0.001

0.302

Neut

85

50

90

< 0.001

86

50

90

< 0.001

0.023

Lymph

15

50

10

< 0.001

14

50

10

< 0.001

0.006

ANC

3838

1305

1975

< 0.001

3895

1200

1900

< 0.001

0.229

4

WBC

3950

1900

3100

< 0.001

3950

2100

3400

< 0.001

0.443

Hb

12.30

12.05

12.05

< 0.001

12.00

12.00

12.00

< 0.001

0.473

Plt

139,000

92,500

128,500

< 0.001

146,000

98,000

132,000

< 0.001

0.969

Neut

90

50

90

< 0.001

90

50

90

< 0.001

0.317

Lymph

10

50

11

< 0.001

10

50

10

< 0.001

0.143

ANC

1975

955

2738

< 0.001

1900

1020

2872

< 0.001

0.548

5

WBC

3100

2500

4500

< 0.001

3400

2500

4900

< 0.001

0.341

Hb

12.05

12.00

12.00

0.095

12.00

12.00

11.50

< 0.001

0.237

Plt

128,500

100,000

151,000

< 0.001

132,000

102,000

159,000

< 0.001

0.974

Neut

90

50

90

< 0.001

90

50

90

< 0.001

0.413

Lymph

11

50

10

< 0.001

10

50

10

< 0.001

0.590

ANC

2738

1350

3895

< 0.001

2872

1250

4410

< 0.001

0.289

6

WBC

4500

3200

6750

< 0.001

4900

3450

6800

< 0.001

0.581

Hb

12.00

12.00

12.00

0.001

11.50

11.40

11.30

< 0.001

0.206

Plt

151,000

111,500

159,500

< 0.001

159,000

110,000

174,000

< 0.001

0.919

Neut

90

50

90

< 0.001

90

50

90

< 0.001

0.663

Lymph

10

50

10

< 0.001

10

50

10

< 0.001

0.743

ANC

3895

1725

5948

< 0.001

4410

1900

6120

< 0.001

0.543

7

WBC

6750

4200

8400

< 0.001

6800

4600

9100

< 0.001

0.050

Hb

12.00

11.90

11.50

< 0.001

11.30

11.30

11.30

0.002

0.342

Plt

159,500

121,000

170,500

< 0.001

174,000

124,000

186,000

< 0.001

0.559

Neut

90

50

90

< 0.001

90

50

90

< 0.001

0.306

Lymph

10

50

10

< 0.001

10

50

10

< 0.001

0.898

ANC

5948

2100

7560

< 0.001

6120

2300

8330

< 0.001

0.146

8

WBC

8400

4950

10,000

< 0.001

9100

5100

10,550

< 0.001

0.395

Hb

11.50

11.35

11.35

< 0.001

11.30

11.25

11.25

< 0.001

0.528

Plt

170,500

124,000

186,500

< 0.001

186,000

124,000

194,500

< 0.001

0.637

Neut

90

50

90

< 0.001

90

50

90

< 0.001

0.781

Lymph

10

50

10

< 0.001

10

50

10

< 0.001

0.838

ANC

7560

2525

9000

< 0.001

8330

2575

9601

< 0.001

0.434

  1. P-value*: Repeated measurements within the groups (Friedman’s test)
  2. P-value**: Repeated measurements between the groups (GEE analysis)